Jazz Pharmaceuticals may extend earnings beat streak with positive ESP

Zacks Investment Research··Read original
2▲1 ▼0Impact / 5
Summary · why it matters

Jazz Pharmaceuticals has a positive Zacks Earnings ESP of +0.41% and a Zacks Rank #3, a combination that historically produces an earnings beat nearly 70% of the time. The company has beaten estimates in its last two quarters, with an average surprise of 18.03%, including a 35.76% beat last quarter when it reported $6.34 per share versus a $4.67 consensus. Its next earnings report is expected on August 3, 2026.

Impact on assets 1

Biotech & Genomic Medicine▲ · 1 stocks
Jazz Pharmaceuticals PLC
JAZZ
▲ PositiveCapitalrelevance

Positive Zacks ESP and historical earnings beat rate suggest upcoming earnings likely beat estimates.

© 2026 MarketIVNews